This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Raymond James analyst Rick Patel downgraded On Holding AG (NYSE:ONON) from Strong Buy to Outperform and cut the price target from $52 to $38. On Holding closed at $30.91 on Tuesday. See how other analysts view this stock.
• Deutsche Bank analyst David Hoang downgraded AtaiBeckley Inc (NASDAQ:ATAI) from Buy to Hold and slashed the price target from $12 to $8. AtaiBeckley shares closed at $7.21 on Tuesday. See how other analysts view this stock.
• BTIG analyst Julian Harrison downgraded Apogee Therapeutics Inc (NASDAQ:APGE) from Buy to Neutral. Apogee Therapeutics closed at $134.69 on Tuesday. See how other analysts view this stock.
• Oppenheimer analyst Trevor Allred downgraded Legend Biotech Corporation (NASDAQ:LEGN) from Outperform to Perform and lowered the price target from $75 to $40. Legend Biotech shares closed at $21.83 on Tuesday. See how other analysts view this stock.
• China Renaissance analyst Yiwen Zhang downgraded Tencent Music Entertainment Group (NYSE:TME) from Buy to Hold and announced a $9.3 price target. Tencent Music closed at $8.72 on Tuesday. See how other analysts view this stock.

Considering buying APGE stock? Here’s what analysts think:

Photo via Shutterstock